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BACKGROUND: An urgent need exists for new treatments of schizophrenia that are effective against a broad range
of symptoms and free of limiting safety issues. ITI-007 is a new molecular entity with a pharmacologic proﬁle that
combines dose-related monoamine modulation with phosphorylation of intracellular signaling proteins.
METHODS: A phase II randomized, double-blind, placebo-controlled, and active-controlled trial was conducted at
eight sites in the United States with randomization of 335 acutely psychotic adults with schizophrenia. ITI-007 (60 mg
and 120 mg), placebo, and risperidone, included for assay sensitivity, were evaluated as monotherapy for 4 weeks.
The primary outcome measure was the Positive and Negative Syndrome Scale total score, with secondary analyses
conducted on symptom subscales.
RESULTS: ITI-007 60 mg (p 5 .017, effect size 5 .4) and risperidone (p 5 .013, effect size 5 .4) demonstrated
antipsychotic efﬁcacy superiority over placebo on the primary end point. The results of secondary analyses reﬂected
improvements in negative and depressive symptoms by ITI-007 60 mg. ITI-007 120 mg did not separate from
placebo. However, both doses of ITI-007 were well tolerated in this patient population, as evidenced by low
discontinuation and adverse event rates, and were associated with a benign metabolic proﬁle as evidenced by
signiﬁcantly lower levels of prolactin, fasting glucose, total cholesterol, and triglycerides than risperidone.
CONCLUSIONS: The mechanistically novel investigational drug ITI-007 was effective for the treatment of
schizophrenia and comparable with placebo on safety measures in this trial. Secondary analyses indicated that
ITI-007 improved negative and depression symptoms and might have expanded therapeutic efﬁcacy in comparison
with current antipsychotic drugs.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2015.08.026Schizophrenia is a debilitating psychotic illness that affects
approximately 1% of the population. Current antipsychotic
drugs (APDs) have therapeutic effects in patients with schiz-
ophrenia predominantly against positive symptoms, such as
hallucinations and delusions (1), but leave most individuals
with signiﬁcant residual symptoms, diminished quality of life,
and enduring functional impairment (2). Treatment early in the
course of the disease and psychosocial support may improve
outcome, but treatment options remain limited.
Most APDs show only modest effectiveness, if any, in
treating the nonpsychotic symptoms of schizophrenia that
are believed to be responsible for the poor social and
academic/vocational functioning characteristics of the illness,
including social withdrawal, ﬂattened affect, depression, and
cognitive impairment (3). Additionally, all currently used APDs
exhibit clinically signiﬁcant side effects of varying types and
severity. So-called ﬁrst-generation APDs are commonly asso-
ciated with extrapyramidal side effects (EPS) such as& 2016 Society of Biological Psychiatry. This is an open access a
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SEE COMMENTARYbradykinesia, rigidity, akathisia, tremor, and tardive dyskinesia,
while many second-generation, or atypical, APDs frequently
lead to weight gain and metabolic alterations such as hyper-
glycemia, insulin resistance, and dyslipidemia (4). Clozapine is
arguably the most efﬁcacious APD, yet is among the most
prone to the aforementioned metabolic disturbances. It is also
associated with an increased incidence of seizures and
potentially lethal side effects of agranulocytosis and myocar-
ditis (5). Consequently, there is tremendous unmet medical
need for safer treatments that are more effective and have a
broader spectrum of efﬁcacy across multiple symptom
domains.
ITI-007 is a new molecular entity with a unique pharmaco-
logic proﬁle that combines dose-related monoamine modu-
lation with phosphorylation of intracellular signaling proteins
(6). While it interacts with several targets that are common to
some existing APDs, its full actions are complex and unique
(7). ITI-007 is a high-afﬁnity serotonin 2A (5-HT2A) receptorrticle under the CC BY-NC-ND license
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neurobiological targets, including D2 receptors. While 5-HT2A
receptor antagonism in addition to D2 receptor antagonism
has been the hallmark of atypical APDs (8), ITI-007 has a wider
separation (sixtyfold) between its afﬁnity for 5-HT2A receptors
and D2 receptors than other APDs, allowing full saturation of
5-HT2A receptors, even at modest levels of dopamine recep-
tor occupancies (7). Moreover, unlike most other anti-
psychotics that are antagonists at D2 receptors both
presynaptically and postsynaptically and unlike aripiprazole
and related compounds that are partial agonists at D2
receptors both presynaptically and postsynaptically, ITI-007
interacts with dopamine receptors in a unique way. At D2
receptors, ITI-007 is a presynaptic partial agonist and post-
synaptic antagonist with functional mesolimbic/mesocortical
selectivity (7). This allows for functional blockade of dopamine
without increasing dopamine turnover and corresponds to
antipsychotic efﬁcacy without motor side effects (7). Above
and beyond 5-HT2A and D2 receptor interactions, ITI-007
increases phosphorylation of mesolimbic GluN2B subunits of
N-methyl-D-aspartate (NMDA) receptors (7). An increase in
GluN2B increases synaptic NMDA activity via subcellular
trafﬁcking to plasma membranes (9). To the extent that a
deﬁcit in glutamatergic function contributes to schizophrenia
symptoms (10,11), indirect enhancement of glutamatergic
NMDA function is predicted to reduce psychosis and improve
cognitive function and negative symptoms. Although inves-
tigational therapeutics targeted solely at direct interaction with
glutamate receptors or glycine transporters have not success-
fully translated into clear clinical beneﬁt, it is recognized
that the interaction between glutamate and dopamine
modulation is important in schizophrenia (12). At serotonin
transporters, ITI-007 inhibits the serotonin transporter (7), an
effect associated with many antidepressant drugs (13). ITI-007
lacks signiﬁcant activity at many receptors (e.g., H1, muscar-
inic, serotonin 2C) that are associated with deleterious effects
experienced with many other APDs (i.e., clinically signiﬁcant
sleep induction, cognitive impairment, weight gain). Thus, by
acting through serotonergic, dopaminergic, and glutamatergic
signaling systems in a mechanistically and neuroanato-
mically selective manner, ITI-007 represents a novel approach
to the treatment of schizophrenia and other neuropsychiatric
disorders.
This study evaluated the efﬁcacy of ITI-007 in schizophrenia
patients and included secondary outcomes of positive, neg-
ative, and depressive symptoms and symptoms associated
with social function. We hypothesized that based on its
pharmacologic proﬁle and preliminary data that ITI-007 would
be an effective APD with efﬁcacy across a broader range of
symptoms in patients presenting with an acute exacerbation
of schizophrenia and excellent tolerability as compared with
placebo and risperidone (one of the most commonly
prescribed APDs).METHODS AND MATERIALS
Study Design
This was a randomized, double-blind, placebo- and active-
controlled, multicenter phase II clinical trial (ITI-007-005)Biological Pconducted at eight sites in the United States from December
2011 to November 2013. Subjects (n 5 335) were randomized
in a 1:1:1:1 ratio across parallel groups to receive ITI-007
(60 mg, 120 mg), placebo, or risperidone (4 mg) as oral
monotherapy once daily in the morning for 4 weeks. Individ-
uals randomized to 120 mg ITI-007 or risperidone received a
single day dose titration (60 mg to 120 mg ITI-007 on day 2; 2
mg to 4 mg risperidone on day 2); 60 mg ITI-007 required no
dose titration. Doses of 60 mg and 120 mg ITI-007 were
selected based on estimated striatal D2 receptor occupancy of
approximately 50% and 70%, respectively, modeled from the
D2 receptor occupancies determined in a positron emission
tomography study at lower doses in healthy volunteers (14). A
dose of risperidone of 4 mg was selected as a positive control
for assay sensitivity based on its mean modal effective dose
determined by the Clinical Antipsychotic Trials of Intervention
Effectiveness (15) and its well-characterized efﬁcacy and
safety proﬁle as one of the most prescribed antipsychotics
in the United States. The risperidone dose and titration
schedule are also within the recommendations of the US Food
and Drug Administration approved label for this drug. Assign-
ment of a randomization number across the study was via an
automated central randomization and trial supply management
system using a computer-generated sequence. The random-
ization assigned a numbered kit containing visually matched
capsules to keep subjects, clinical site staff, and study over-
sight team blinded.Participants
Patients, 18 to 55 years of age, with a diagnosis of schizo-
phrenia conﬁrmed by a Structured Clinical Interview for DSM
Disorders–Clinical Trials Version (16) were eligible for partic-
ipation if experiencing an acute exacerbation of psychosis
deﬁned as a score of $40 on the 18-item Brief Psychiatric
Rating Scale (item range 1–7) with a score of $4 on $2 of the
positive symptom items: suspiciousness, conceptual disorga-
nization, hallucinatory behavior, or unusual thought content.
The current acute episode was required to have started within
4 weeks of screening with an independent informant verifying
that symptom severity represented an acute exacerbation for a
given individual. Individuals were required to have shown
previous treatment response to APD therapy and thus be
neither treatment-naïve nor treatment-resistant. Diagnosis and
symptom severity at screening were rated by study investi-
gators and conﬁrmed by independent psychiatrists or clinical
psychologists to ensure inclusion of an appropriate patient
population (Clintara LLC, Boston, Massachusetts) (17).
Patients who met any of the following exclusion criteria were
not included in the study: unable to provide informed consent;
pregnant/breastfeeding; dementia/delirium/mental retardation/
epilepsy/drug-induced psychosis/brain trauma; schizoaffec-
tive disorder/bipolar disorder/acute mania/major depression
with psychotic features; imminent danger to self or others;
suicidal ideation/behavior; unstable living environment; use of
depot antipsychotic within one treatment cycle before base-
line; use of any APD within screening period; use of speciﬁc
agents with known interaction with 5-HT2A receptors; clin-
ically signiﬁcant abnormal laboratory values or clinical ﬁnd-
ings; uncontrolled angina/recent history of myocardialsychiatry June 15, 2016; 79:952–961 www.sobp.org/journal 953
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ical/renal/hepatic/endocrinological/neurological/cardiovascu-
lar disease; history of neuroleptic malignant syndrome; human
immunodeﬁciency virus; hepatitis B or C with evidence of
active liver disease; substance abuse/dependence; positive
drug/alcohol screen; likely drug allergy/sensitivity; prior partic-
ipation in a study with ITI-007 or recent exposure to any
investigational product; unable to be safely discontinued from
current antipsychotic or other psychotropic medications; and
any patient judged by the investigator to be inappropriate for
study participation.
All candidates for the study with signed informed consent
were admitted to an inpatient unit. Baseline efﬁcacy measures
were assessed on day 1, following the #7-day drug-free
screening period and before randomization on day 1. Those
who met eligibility criteria were randomized to treatment and
maintained as inpatients throughout the 28-day treatment
period. Following the treatment period, patients were stabi-
lized on standard of care APDs for 5 days before discharge
and returned to the clinic for a follow-up safety visit 2 weeks
following the last dose of study medication.
The study was conducted in compliance with the principles
of the Good Clinical Practice guidelines of the Food and Drug
Administration and International Conference on Harmoniza-
tion. The protocol, informed consent document, and other
study-speciﬁc materials were approved by a central Institu-
tional Review Board. All subjects provided written informed
consent before study-speciﬁc procedures were conducted.
The study was completed as originally designed, without
protocol amendment.
Assessments
Participating subjects underwent baseline and weekly assess-
ment with the Positive and Negative Syndrome Scale
(PANSS), a well-validated 30-item scale used to measure
symptoms of schizophrenia (18). Individuals were rated on
this scale by remote central raters (MedAvante, Inc., Trenton,
New Jersey) using audiovisual communication; central raters
were mental health professionals trained to a high degree of
interrater reliability and blinded to study design, treatment, and
time point of assessment (19). Calgary Depression Scale for
Schizophrenia (CDSS) was used to assess symptoms of
depression. Safety end points included assessment of adverse
events, motor function (Simpson-Angus Scale, Barnes Aka-
thisia Rating Scale, and Abnormal Involuntary Movement
Scale), suicidal ideation and behavior (Columbia Suicide
Severity Rating Scale), clinical laboratory assessments, vital
signs, and electrocardiograms. The CDSS and safety scales
were rated by site raters after receiving training for stand-
ardization across sites.
Statistical Analysis
The primary efﬁcacy end point, deﬁned a priori, was change
from baseline to day 28 (or end point) on the PANSS total
score. The primary treatment effect comparison was per-
formed using a mixed-effect model repeated measures
(MMRM) method, also deﬁned a priori, with the Bonferroni
correction applied to adjust for multiple comparisons; each
comparison (60 mg ITI-007 vs. placebo; 120 mg ITI-007 vs.954 Biological Psychiatry June 15, 2016; 79:952–961 www.sobp.org/jplacebo) was tested at two-sided signiﬁcance level
α 5 .05. The treatment effect was analyzed using the MMRM
method, including change from baseline to day 28 as the
response variable and terms of treatment, baseline variable,
time point (treated as a categorical variable), as well as
interaction between treatment and time point. An unstructured
covariance matrix was used to model the correlation among
repeated measurements. The Kenward-Roger adjustments
were used with restricted maximum likelihood to make proper
statistical inferences. The primary analysis was conducted in
the modiﬁed intent-to-treat (ITT) population, deﬁned as having
a valid baseline PANSS assessment and at least one valid
postdose assessment. Determination of exclusion of subjects
from the ITT population was made on blinded data before
database lock. In addition, a sensitivity analysis, also deﬁned a
priori, was performed using analysis of covariance (ANCOVA)
with last observation carried forward (LOCF) to assess the
main effect of treatment, adjusted for baseline score. A
responder analysis, deﬁned a priori, calculated the percent
of subjects with $30% reduction on PANSS total score
(subtracting 30 from the PANSS score so that a complete
response is represented by 100% decrease; p value com-
puted using Cochran Mantel-Haenszel test).
Secondary (post hoc) analyses included the PANSS sub-
scales analyzed using ANCOVA with LOCF in the ITT sample.
In addition, a priori deﬁned subgroup analyses were con-
ducted in patients completing 28 days of treatment for those
symptoms such as negative symptoms and depression that
are thought to require longer treatment duration to detect a
response. These subgroup analyses were not powered to
detect statistically signiﬁcant differences but designed to
illustrate magnitude of response as indicated by the effect
size (ES). ES (Cohen’s d) was calculated by dividing the
difference of the means in change from baseline to end point
(treatment – placebo) by the common standard deviation.
Treatment effects were examined in a patient subgroup with
prominent negative symptoms at baseline (a priori deﬁned as
having a score of $4 on $3 items on the PANSS negative
symptoms subscale at baseline, i.e., blunted affect, emotional
withdrawal, poor rapport, passive apathetic social withdrawal,
difﬁculty in abstract thinking, lack of spontaneity and ﬂow of
conversation, and stereotyped thinking) and a subgroup with
depression symptoms at baseline (a priori deﬁned as having a
CDSS score .6 at baseline). In addition, a post hoc analysis
was conducted on the ITT sample to determine the effects of
ITI-007 on a PANSS-derived prosocial factor (20) that consists
of PANSS items: G16: Active Social Avoidance, N2: Emotional
Withdrawal, N4: Passive Social Withdrawal, N7: Stereotyped
Thinking, P3: Hallucinatory Behavior, and P6: Suspiciousness/
Persecution.
Safety analyses were conducted in all patients who were
randomized and received at least one dose of study medi-
cation. Treatment-emergent adverse events were summarized
and relative risk (ratio of frequency of treatment-emergent
adverse events on drug relative to placebo), the associated
95% conﬁdence interval, and the p value using Fisher’s exact
test were reported. A post hoc comparison of ITI-007 with
risperidone on key safety measures was conducted using
t tests for difference in means in independent treatment
groups based on change from baseline in patients completingournal
Table 1. Subject Demographics and Baseline Characteristics
Placebo ITI-007 60 mg ITI-007 120 mg Risperidone 4 mg
Demographics (Safety Population) n 5 85 n 5 84 n 5 83 n 5 82
Male, n (%) 65 (76.5) 66 (78.6) 72 (86.7) 73 (89.0)
Age (years, mean 6 SD), percent #40 years 40.5 6 9.8, 47.1 38.3 6 10.0, 54.8 41.1 6 8.9, 43.4 40.7 6 9.3, 43.9
Race, n (%)
Black 65 (76.5) 70 (83.3) 62 (74.7) 64 (78.0)
White 17 (20.0) 13 (15.5) 16 (19.3) 16 (19.5)
Asian 1 (1.2) 0 0 2 (2.4)
Othera 2 (2.4) 1 (1.2) 5 (6.0) 0
Non-Hispanic, n (%) 81 (95.3) 81 (96.4) 76 (91.6) 80 (97.6)
Baseline (ITT Population) n 5 80 n 5 76 n 5 80 n 5 75
Paranoid schizophrenia, n (%) 78 (97.5) 74 (97.4) 76 (95.0) 71 (94.7)
Years since ﬁrst diagnosis, mean 6 SD 16.7 6 10.4 16.0 6 9.4 17.0 6 10.2 15.2 6 9.4
Screening BPRS, mean 6 SD 56.5 6 8.0 55.6 6 7.0 55.5 6 7.7 56.6 6 8.2
Baseline PANSS, mean 6 SD 86.3 6 13.1 88.1 6 11.0 84.6 6 11.6 86.1 6 12.2
Positive symptoms subscale, mean 6 SD 24.6 6 4.6 24.8 6 4.2 23.8 6 4.5 24.2 6 4.1
Negative symptoms subscale, mean 6 SD 19.8 6 4.8 21.0 6 4.1 19.8 6 4.1 20.7 6 5.1
General psychopathology subscale, mean 6 SD 41.9 6 7.0 42.2 6 7.0 41.0 6 6.9 41.3 6 6.6
Baseline (Subgroup With Prominent Negative Symptoms) n 5 29 n 5 33 n 5 25 n 5 33
Negative symptoms subscale, mean 6 SD 23.3 6 4.2 23.5 6 3.1 23.9 6 3.0 23.2 6 3.9
Baseline (Subgroup With Depression Symptoms) n 5 14 n 5 7 n 5 13 n 5 11
Baseline PANSS 91.9 6 10.9 95.1 6 11.1 85.3 6 15.4 92.7 6 12.5
CDSS, mean 6 SD 9.3 6 2.8 8.0 6 1.0 8.9 6 1.7 9.8 6 2.6
BPRS, Brief Psychiatric Rating Scale; CDSS, Calgary Depression Scale for Schizophrenia; ITT, intent to treat; PANSS, Positive and Negative
Syndrome Scale.
aOther race includes American Indian/Native Alaskan, Native Hawaiian/Other Paciﬁc Islander, or Other.
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gain was calculated by the sum of all sites for (placebo-
adjusted mean in site 3 number of subjects in site)/sum of all
sites for (number of subjects in site).RESULTS
Subject Characteristics
A total of 335 patients with schizophrenia were randomized
across four treatment groups. There were no systematic
differences in prior antipsychotic therapy; all APDs, in patients
who were receiving them, were discontinued at the start of the
screening period. The safety population (n 5 334) included all
subjects who received $1 dose of study medication; one
subject was randomized but withdrew before receiving study
medication and was excluded from the safety population. The
ITT population included 311 subjects. Exclusions from the ITT
population included a few instances in which there was no
predose baseline assessment of the PANSS, in error, or
subjects who withdrew consent before the ﬁrst postdose
assessment of the PANSS was conducted and refused all
end-of-study procedures. Demographics and baseline char-
acteristics were similar across treatment groups (Table 1).
Eighty-one percent of the 335 subjects completed study
treatment and very few patients were lost to follow-up after
discharge from the inpatient unit, providing a study completion
rate of 74% (Figure 1).Biological PAntipsychotic Efﬁcacy of ITI-007
ITI-007 60 mg signiﬁcantly improved schizophrenia symptoms
on the primary end point, change from baseline on the
total PANSS to day 28, compared with placebo (least squares
[LS] mean change 213.2 points vs. 27.4 points; p 5 .017,
MMRM, ES 5 .4) (Table 2). ITI-007 120 mg did not signiﬁcantly
separate from placebo on the total PANSS at day 28 (LS mean
change 28.3 vs. 27.4; p 5 .708). Risperidone (4 mg) differed
from placebo on the total PANSS, demonstrating assay
sensitivity (LS mean change 213.4 points vs. 27.4 points;
p 5 .013, MMRM, ES 5 .4). The sensitivity analysis by
ANCOVA LOCF conﬁrmed the results of the MMRM analysis
(Table 2). The responder analysis indicated that a similar
proportion of patients (40%) randomized to 60 mg ITI-007 or
risperidone improved on the PANSS total by $30% (Table 2).
ITI-007 60 mg and risperidone signiﬁcantly reduced positive
symptoms and general psychopathology relative to the pla-
cebo group on the PANSS subscales; ITI-007 120 mg reduced
positive symptoms and general psychopathology, but the
improvement relative to the placebo group did not reach
statistical signiﬁcance (Figure 2). The effect of the interaction
between treatment and time point on change from baseline in
PANSS total score and in PANSS positive subscale was not
statistically signiﬁcant (F9,783.2 5 1.56, p 5 .123 and F9,845.5 5
1.27, p 5 .252, respectively). Negative symptoms improved
only with 60 mg ITI-007, though the improvement did not
reach statistical signiﬁcance (Table 2), likely due to relatively
low negative symptomatology at baseline in this acutesychiatry June 15, 2016; 79:952–961 www.sobp.org/journal 955
Figure 1. Study ﬂow diagram and
patient disposition.
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improve negative symptoms.
Results From Subgroups of Patients With Negative
and Depression Symptoms
Approximately a third of the patients met the criteria for
prominent negative symptoms at baseline and were included
in an exploratory a priori speciﬁed subgroup analysis of
treatment effects on negative symptoms in this acutely
exacerbated population (Table 1). In this subgroup, 60 mg
ITI-007 reduced the severity of symptoms as reﬂected by the
PANSS negative symptoms subscale (ES 5 .34). In contrast,
the improvement in negative symptoms with risperidone was
minimally less than that with placebo (ES 5 2.02) (Table 2).
Thirteen percent of patients met the criteria of comorbid
symptoms of depression at baseline and were included in this
subgroup analysis (Table 1). ITI-007 60 mg signiﬁcantly
reduced the total PANSS score and the CDSS score in this
subgroup with an ES of approximately 1 on both measures,
while risperidone showed substantially smaller ESs (Table 2).
Because this differential response proﬁle for ITI-007 is
related to improved social function, we added a post hoc
analysis of the PANSS-derived prosocial factor, a cluster of
symptoms corresponding to social function (20). ITI-007 (60
mg) signiﬁcantly (p , .001) improved prosocial behavior as
deﬁned as a reduction in the PANSS prosocial factor with an956 Biological Psychiatry June 15, 2016; 79:952–961 www.sobp.org/jES of .6, suggesting that 60 mg ITI-007 might be particularly
effective against this cluster of symptoms. In contrast, risper-
idone had a lower ES of .4 (p , .01) similar to its ES on the
PANSS total score (Table 2).
Safety of ITI-007
ITI-007 was safe and well tolerated in individuals with schiz-
ophrenia. There were no serious adverse events associated
with ITI-007. Two treatment-emergent serious adverse events
(worsening of schizophrenia/psychotic disorder) occurred dur-
ing the trial, one in a patient randomized to risperidone and
one patient randomized to placebo. Five patients discontinued
study treatment due to an adverse event: two patients
randomized to ITI-007 (one dry mouth and one worsening of
schizophrenia) and three patients randomized to risperidone
(two cases of akathisia and one blood creatine phosphokinase
increase). The relative risk of any treatment-emergent adverse
event for 60 mg ITI-007 (1.14; 95% conﬁdence interval: .89,
1.46) did not differ from placebo (p 5 .346). The relative risk
was 1.30 for 120 mg ITI-007 (p 5 .024) and 1.25 for
risperidone (p 5 .077). The most frequent adverse event
reported in the study was somnolence/sedation (placebo 5
13%, 60 mg ITI-007 5 17%, risperidone 5 21%, and 120 mg
ITI-007 5 32.5%) (Table 3). Neither dose of ITI-007 was
associated with EPS as measured by the Simpson-Angus
Scale, Barnes Akathisia Rating Scale, and Abnormalournal
Table 2. Primary and Secondary Analyses Demonstrated Antipsychotic Efﬁcacy of ITI-007 at a Dose of 60 mg Including
Prospective Subgroup Analyses That Demonstrated a Differentiating Response Proﬁle of ITI-007 at a Dose of 60 mg and a
Post Hoc Analysis of a PANSS-Derived Prosocial Factor
LS Mean (6 SEM) Change From
Baseline on Day 28
LS Mean Difference From
Placebo (Rounded)
p
Value
Effect
Size
Total PANSS (MMRM) – Primary
Placebo (n 5 80) 27.4 6 1.68 n/a n/a n/a
60 mg ITI-007 (n 5 76) 213.2 6 1.69 25.8 .017 .42
120 mg ITI-007 (n 5 80) 28.3 6 1.68 2.9 .708 .07
4 mg Risperidone (n 5 75) 213.4 6 1.72 26.0 .013 .44
Total PANSS (ANCOVA-LOCF) – Sensitivity
Placebo (n 5 80) 26.3 6 1.6 n/a n/a n/a
60 mg ITI-007 (n 5 76) 212.3 6 1.7 26.0 .011 .41
120 mg ITI-007 (n 5 80) 27.7 6 1.6 21.4 .558 .09
4 mg Risperidone (n 5 75) 212.6 6 1.7 26.3 .008 .43
PANSS Positive Subscale (ANCOVA-LOCF)
Placebo (n 5 80) 22.3 6 .5 n/a n/a n/a
60 mg ITI-007 (n 5 76) 24.7 6 .5 22.4 .002 .50
120 mg ITI-007 (n 5 80) 23.2 6 .5 2.8 .272 .17
4 mg Risperidone (n 5 75) 24.8 6 .5 22.4 .002 .51
PANSS Negative Subscale (ANCOVA-LOCF)
Placebo (n 5 80) 2.3 6 .5 n/a n/a n/a
60 mg ITI-007 (n 5 76) 21.2 6 .5 2.9 .230 .19
120 mg ITI-007 (n 5 80) .5 6 .5 .7 .319 .16
4 mg Risperidone (n 5 75) 2.4 6 .5 2.1 .914 .02
PANSS General Psychopathology Subscale (ANCOVA-LOCF)
Placebo (n 5 80) 23.6 6 .9 n/a n/a n/a
60 mg ITI-007 (n 5 76) 26.3 6 .9 22.6 .040 .33
120 mg ITI-007 (n 5 80) 25.0 6 .9 21.4 .271 .17
4 mg Risperidone (n 5 75) 27.5 6 .9 23.8 .003 .48
n (%) Rate Difference % (95% CI) p Value
Total PANSS Responder Analysis $ 30% Reduction
Placebo (n 5 80) 18 (22.5) n/a n/a
60 mg ITI-007 (n 5 76) 31 (40.8) 18.3 (3.9, 32.6) .014
120 mg ITI-007 (n 5 80) 20 (25.0) 2.5 (210.7, 15.7) .711
4 mg Risperidone (n 5 75) 30 (40.0) 17.5 (3.1, 31.9) .019
Mean (6 SEM) Change From
Baseline on Day 28
Mean Difference From
Placebo (Rounded)
p
Value
Effect
Size
PANSS Negative Subscale in Subgroup With Prominent Negative Symptoms at Baseline
Placebo (n 5 29) 21.3 6 .92 n/a n/a n/a
60 mg ITI-007 (n 5 33) 23.0 6 .88 21.6 .206 .34
120 mg ITI-007 (n 5 25) 21.1 6 .93 .2 .865 0
4 mg Risperidone (n 5 33) 21.2 6 .80 .2 .893 0
Total PANSS in Subgroup With Depression Symptoms at Baseline
Placebo (n 5 14) 212.4 6 3.89 n/a n/a n/a
60 mg ITI-007 (n 5 7) 231.7 6 7.31 219.4 .018 1.13
120 mg ITI-007 (n 5 12) 214.2 6 3.51 21.8 .736 .14
4 mg Risperidone (n 5 11) 220.6 6 3.89 28.3 .152 .60
CDSS in Subgroup With Depression Symptoms at Baseline
Placebo (n 5 14) 25.4 6 1.00 n/a n/a n/a
60 mg ITI-007 (n 5 7) 27.7 6 .42 22.4 .044 .99
120 mg ITI-007 (n 5 13) 25.6 6 .74 2.3 .839 .09
4 mg Risperidone (n 5 11) 27.2 6 1.31 21.8 .271 2.48
LS Mean (6 SEM) Change From
Baseline on Day 28
LS Mean Difference From
Placebo (Rounded)
p
Value
Effect
Size
Post Hoc Analysis of PANSS-Derived Prosocial Factor (ANCOVA-LOCF)
Placebo (n 5 80) 22.5 6 .5 n/a n/a n/a
60 mg ITI-007 (n 5 76) 25.0 6 .5 22.5 ,.001 .59
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Table 2. Continued
LS Mean (6 SEM) Change From
Baseline on Day 28
LS Mean Difference From
Placebo (Rounded)
p
Value
Effect
Size
120 mg ITI-007 (n 5 80) 23.3 6 .5 20.8 .243 .19
4 mg Risperidone (n 5 75) 24.2 6 .5 21.7 .01 .42
ANCOVA, analysis of covariance; CDSS, Calgary Depression Scale for Schizophrenia; CI, conﬁdence interval; LOCF, last observation carried
forward; LS, least squares; MMRM, mixed-effects model repeated measures; n/a, not applicable; PANSS, Positive and Negative Syndrome Scale;
SEM, standard error of the mean.
ITI-007 Randomized Trial in Schizophrenia
Biological
PsychiatryInvoluntary Movement Scale (Supplemental Table S1). Nota-
bly, whereas risperidone caused akathisia as a treatment-
emergent adverse event in 7% of subjects, ITI-007 at both
doses was similar to placebo at 1% to 2%. Similarly,
benztropine was allowed as a rescue medication for EPS
and was used in seven patients in the risperidone group
(9.3%) during the 28-day treatment period, in contrast to 1 to 2
subjects in each of the ITI-007 or placebo groups (1.3% to
2.5%). Weight gain for placebo subjects varied considerably
from site to site, ranging from an average loss of 4.5 kg to an
average gain of 4.8 kg (Supplemental Table S2), suggesting
median weight gain might be more representative than mean
changes. Median weight gain (change from screening at day
27 to day 28) was about 1 kg for patients randomized to
placebo, 60 mg ITI-007, or 120 mg ITI-007 and about 2.5 kg
for patients randomized to risperidone (Table 3). Placebo-
adjusted mean weight gain by site (change from screening atStudy DayLS
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Figure 2. ITI-007 at a dose of 60 mg demonstrated antipsychotic efﬁcacy
as measured by the primary end point, least squares (LS) mean (standard
error of the mean [SEM]) change from baseline in Positive and Negative
Syndrome Scale (PANSS) total score (mixed-effects model repeated
measures [MMRM]). *p , .05 vs. placebo. ITT, intent to treat.
958 Biological Psychiatry June 15, 2016; 79:952–961 www.sobp.org/jday 27 to day 28) indicated a gain of .3 to .4 kg for both doses
of ITI-007 and a gain of 2.3 kg for risperidone. Despite the site-
to-site variability, post hoc analyses indicated a trend toward
signiﬁcantly less weight gain in ITI-007 groups than for
risperidone (p 5 .087 for 60 mg vs. risperidone; p 5 .074 for
120 mg vs. risperidone). In post hoc comparisons to risper-
idone (Figure 3), ITI-007 showed statistically signiﬁcantly lower
prolactin levels (ITI-007 60 mg and 120 mg, p , .001 vs.
risperidone), fasting glucose (ITI-007 60 mg, p 5 .007; ITI-007
120 mg, p 5 .023), total cholesterol (ITI-007 60 mg, p 5 .012;
ITI-007 120 mg, p 5 .004), and triglycerides (ITI-007 60 mg,
p 5 .074; ITI-007 120 mg, p 5 .002). Levels of insulin, glucose,
triglycerides, and prolactin remained low while subjects were
on ITI-007 but increased when switched to standard of care
antipsychotic medication for stabilization after the 28-day
study treatment period (Supplemental Figure S1).
There were no serious adverse events related to
ITI-007. There were no clinically meaningful changes in
safety measures with ITI-007, including cardiovascular safety
issues.
DISCUSSION
ITI-007 60 mg demonstrated a statistically and clinically
signiﬁcant reduction in schizophrenia symptoms in compar-
ison with placebo, meeting the primary end point of this trial.
Its therapeutic effect on total PANSS was comparable with
risperidone, a widely used APD, with an ES of .4 in the range
of other effective antipsychotics tested in 4-week treatment
trials (21). In addition, individuals treated with 60 mg ITI-007
exhibited improvement across a broad range of symptoms,
beyond psychosis, including general psychopathology and
negative and depressive symptoms, the latter two of which are
believed to be associated with social function. Importantly, the
change in negative symptoms was independent of improve-
ment in positive symptoms, depression, or EPS. This is
supported by the fact that risperidone’s improvement of
positive symptoms occurred without corresponding improve-
ment and even a worsening of some negative symptoms, and
there was no correlation between change from baseline on
positive symptoms and change from baseline on negative
symptoms in the overall ITT population (R2 5 .06). Moreover,
improvement of negative symptoms with ITI-007 did not
correspond to change in depression or EPS. However, a
severely ill subset of patients with schizophrenia and comorbid
depression (deﬁned a priori by explicit criteria, with higher
baseline PANSS scores than the entire ITT sample), exhibited
a robust response to ITI-007 60 mg including improved
depressive and psychotic symptoms. Improvement in the
PANSS-derived prosocial factor reﬂects an improvement ofournal
Table 3. Adverse Event and Safety Proﬁle (Safety Population)
Placebo (n 5 85) ITI-007 60 mg (n 5 84) ITI-007 120 mg (n 5 83) Risperidone 4 mg (n 5 82)
TEAEs Occurring in at Least 5% of Subjects in Either ITI-007 Treatment Group and Considered at Least Possibly Related to Study Drug, n (%)
Sedation/somnolence 11 (12.9) 14 (16.7) 27 (32.5) 17 (20.7)
Dry mouth 2 (2.4) 4 (4.8) 7 (8.4) 5 (6.1)
Nausea 1 (1.2) 5 (6.0) 4 (4.8) 4 (4.9)
Dizziness 1 (1.2) 4 (4.8) 7 (8.4) 1 (1.2)
Other TEAEs Common With Risperidone, n (%)
Akathisia 2 (2.3) 1 (1.2) 2 (2.4) 6 (7.3)
Tachycardia 0 1 (1.2) 0 4 (4.9)
Change From Screening (Day 27) to Day 28 (All Inpatient) on Body Weight (kg)
Mean (SD) .8 (3.46) 2.0 (3.10) 1.9 (3.35) 3.0 (3.69)
Median .8 1.0 1.1 2.5
Placebo-adjusted by site mean n/a .4 .3 2.3
Proportion With .7% Increase From Screening in Body Weight
x/n completing 28 days (%) 4/67 (6.0) 9/69 (13.0) 12/69 (17.4) 13/68 (19.1)
Difference from placebo, p value n/a .162 .039 .022
n/a, not applicable; TEAEs, treatment-emergent adverse events.
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suspiciousness. ITI-007 60 mg showed a tolerability and
safety proﬁle similar to placebo and signiﬁcantly better than
risperidone on several clinically relevant outcomes in a post
hoc head-to-head comparison for those subjects completing
28 days of treatment.
These results indicate signiﬁcant therapeutic effect and
favorable side effect proﬁle of ITI-007, in contrast to currently
approved APDs that are thought to exhibit safety issues that
include EPS, weight gain, changes in glucose and lipid
metabolism, hyperprolactinemia, and cardiovascular and cer-
ebrovascular risks (22–24). Young and ﬁrst-episode patients
with schizophrenia are at a particularly increased risk for
obesity, dyslipidemia, and cardiovascular disease with many
of the currently used APDs (25). It is also of interest with
respect to cardiovascular safety that ITI-007 at both doses did
not prolong corrected QT intervals and did not cause sus-
tained heart rate elevations.
It is puzzling that the higher dose of 120 mg ITI-007 was not
as therapeutically effective as 60 mg ITI-007 in this study.
Without a clear reason to explain this result, we can only
speculate that the lack of apparent therapeutic efﬁcacy of the
120 mg dose could be due to a higher frequency of side
effects, speciﬁcally somnolence/sedation. Although somno-
lence/sedation was mostly mild and did not result in early
discontinuations, the occurrence of somnolence/sedation
might have affected patients’ behavior and subjective reports
and thus obscured therapeutic effects and the ability of
centralized rating procedures to accurately assess the extent
of patients’ symptoms. Another possibility is that the lack of
improvement in negative symptoms associated with higher
sedation/somnolence could have contributed to the lack of
separation of 120 mg ITI-007 on the total PANSS despite
some improvements on positive symptoms and general
psychopathology. Although unlikely, it is also possible that
varying receptor afﬁnities occurring at the higher (120 mg)
dose alters ITI-007’s therapeutic activity.
The broader spectrum of ITI-007’s therapeutic effects that
are suggested based on secondary analyses of negative andBiological Pdepressive symptom enriched, albeit small, subgroups
(deﬁned a priori) must be conﬁrmed in future studies. Caution
is warranted in making such conclusions pending further
investigation, as such claims have been made in the past
only to not be born out subsequently (26). The current design
in the acute phase of the illness was not intended to
deﬁnitively address improvements on symptoms other than
positive symptoms. Further investigations are warranted to
examine the effects of ITI-007 on primary negative or depres-
sive symptoms in stable patients with predominant/persistent
negative symptoms or depression, respectively, to extend the
ﬁndings of improvement in these symptom domains in
patients with acute symptoms.
In summary, ITI-007 is a mechanistically novel investiga-
tional new drug that was found to be safe, well tolerated, and
effective for symptoms associated with schizophrenia in a
rigorously designed and executed 28-day clinical trial.ACKNOWLEDGMENTS AND DISCLOSURES
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